0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessIn patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals.
John W. Eikelboom, Jackie Bosch, Stuart J. Connolly, Jessica Tyrwitt, Keith A.A. Fox, Eva Muehlhofer, Christoph Neumann, Christoph Tasto, Shrikant I. Bangdiwala, Rafael Díaz, Marco Alings, Gilles R. Dagenais, Darryl P. Leong, Eva Lonn, Álvaro Avezum, Leopoldo Soares Piegas, Petr Widimský, Alexander Parkhomenko, Deepak L. Bhatt, Kelley R. Branch, Jeffrey L. Probstfield, Patricio López‐Jaramillo, Lars Rydén, Nana Pogosova, Katalin Keltai, Matyàs Keltai, Georg Ertl, Stefan Störk, Antonio L Dans, Fernando Laņas, Yan Liang, Jun Zhu, Christian Torp‐Pedersen, Aldo Maggioni, Patrick Commerford, Tomasz J. Guzik, Thomas Vanassche, Peter Verhamme, Martin O’Donnell, Andrew M. Tonkin, George Varigos, Dragoş Vinereanu, Camillo Felix, Jae‐Hyung Kim, Khairul Shafiq Ibrahim, Basil S. Lewis, Kaj Metsärinne, Victor Aboyans, Philippe Gabríel Steg, Masatsugu Hori, Ajay K. Kakkar, Sonia S. Anand, André Lamy, Mukul Sharma, Salim Yusuf (2022). Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. , 8(8), DOI: https://doi.org/10.1093/ehjcvp/pvac023.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2022
Authors
55
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1093/ehjcvp/pvac023
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
